JP2024515536A5 - - Google Patents

Info

Publication number
JP2024515536A5
JP2024515536A5 JP2023561116A JP2023561116A JP2024515536A5 JP 2024515536 A5 JP2024515536 A5 JP 2024515536A5 JP 2023561116 A JP2023561116 A JP 2023561116A JP 2023561116 A JP2023561116 A JP 2023561116A JP 2024515536 A5 JP2024515536 A5 JP 2024515536A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
amino acid
cdr
drug conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023561116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515536A (ja
JP7579991B2 (ja
Filing date
Publication date
Priority claimed from EP21170941.5A external-priority patent/EP4066899A1/en
Priority claimed from EP21172723.5A external-priority patent/EP4086284A1/en
Application filed filed Critical
Priority claimed from PCT/EP2022/058629 external-priority patent/WO2022207825A1/en
Publication of JP2024515536A publication Critical patent/JP2024515536A/ja
Publication of JP2024515536A5 publication Critical patent/JP2024515536A5/ja
Application granted granted Critical
Publication of JP7579991B2 publication Critical patent/JP7579991B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023561116A 2021-03-31 2022-03-31 抗ネクチン－４抗体エキサテカンコンジュゲート Active JP7579991B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP21166441.2 2021-03-31
EP21166441 2021-03-31
EP21170941.5 2021-04-28
EP21170941.5A EP4066899A1 (en) 2021-03-31 2021-04-28 Anti-nectin-4 antibody
EP21172723.5 2021-05-07
EP21172723.5A EP4086284A1 (en) 2021-05-07 2021-05-07 Anti-nectin-4 antibody exatecan conjugates
EP21209332.2 2021-11-19
EP21209332 2021-11-19
PCT/EP2022/058629 WO2022207825A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4 antibody exatecan conjugates

Publications (3)

Publication Number Publication Date
JP2024515536A JP2024515536A (ja) 2024-04-10
JP2024515536A5 true JP2024515536A5 (enExample) 2024-08-13
JP7579991B2 JP7579991B2 (ja) 2024-11-08

Family

ID=80999114

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023561116A Active JP7579991B2 (ja) 2021-03-31 2022-03-31 抗ネクチン－４抗体エキサテカンコンジュゲート
JP2023561035A Active JP7579990B2 (ja) 2021-03-31 2022-03-31 抗ネクチン－４抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023561035A Active JP7579990B2 (ja) 2021-03-31 2022-03-31 抗ネクチン－４抗体およびその使用

Country Status (18)

Country Link
US (4) US20240173424A1 (enExample)
EP (2) EP4314057A1 (enExample)
JP (2) JP7579991B2 (enExample)
KR (2) KR20240028330A (enExample)
AU (2) AU2022250867A1 (enExample)
BR (1) BR112023017728A2 (enExample)
CA (2) CA3212655A1 (enExample)
CL (2) CL2023002907A1 (enExample)
CO (2) CO2023012821A2 (enExample)
CR (2) CR20230469A (enExample)
DO (2) DOP2023000213A (enExample)
EC (2) ECSP23073625A (enExample)
IL (2) IL305954A (enExample)
JO (2) JOP20230238A1 (enExample)
MX (2) MX2023011563A (enExample)
PE (2) PE20240724A1 (enExample)
SA (1) SA523450918B1 (enExample)
WO (3) WO2022207822A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023011563A (es) * 2021-03-31 2024-02-08 Emergence Therapeutics Gmbh Conjugados de anticuerpo anti-nectina-4 y exatecano.
EP4285935A1 (en) * 2022-06-03 2023-12-06 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4344707A1 (en) * 2022-09-29 2024-04-03 Emergence Therapeutics AG New anti-nectin-4 antibody drug conjugates
EP4461317A1 (en) * 2023-05-12 2024-11-13 Emergence Therapeutics GmbH Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof
EP4725964A1 (en) * 2023-06-08 2026-04-15 Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. Antibody binding to nectin-4 and use thereof
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン－４抗体及び抗体－薬物コンジュゲート
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
EP4534102A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130088116A (ko) * 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
EP3347048B1 (en) * 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
EP3546448B1 (en) * 2016-11-25 2022-04-06 Mabwell (Shanghai) Bioscience Co., Ltd. Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
US11274160B2 (en) * 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
EP3700577A1 (en) * 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
WO2020216947A1 (en) * 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
AU2020364959B2 (en) * 2019-10-07 2026-07-09 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for Nectin-4 and uses thereof
WO2021143741A1 (zh) * 2020-01-15 2021-07-22 北京海步医药科技有限公司 靶向多肽-药物缀合物及其用途
CN114845740B (zh) * 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
MX2023011563A (es) * 2021-03-31 2024-02-08 Emergence Therapeutics Gmbh Conjugados de anticuerpo anti-nectina-4 y exatecano.
EP4534101A1 (en) * 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload

Similar Documents

Publication Publication Date Title
JP2024520188A5 (enExample)
AU2022241522B2 (en) Bispecific antibody to a-syn/igf1r and use thereof
JP7579991B2 (ja) 抗ネクチン－４抗体エキサテカンコンジュゲート
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP2022506072A5 (enExample)
TW202128773A (zh) 抗人Trop-2抗體及其應用
RU2012142311A (ru) Интерлейкин-13-связывающие белки
JP7726534B2 (ja) 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途
WO2014065402A1 (ja) 抗ヒトｃｄ４０モノクローナル抗体及びその利用
FI4200018T3 (fi) Anti-par-2-vasta-aineet ja niiden käyttömenetelmät
JP2023509214A5 (enExample)
JP2023549316A5 (enExample)
JP2023509215A5 (enExample)
US20260028424A1 (en) Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof
KR20250127137A (ko) 항-cmet 항체, 항체-약물 접합체, 이의 제조 방법 및 용도
CN114450025A (zh) 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症
IL321677A (en) Anti-PDL1 antibodies, multispecific antibodies, and methods of use
JP2023546277A5 (enExample)
US20250197501A1 (en) Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers
JP2024547020A5 (ja) 多重特異性抗体、免疫コンジュゲート、抗原認識受容体、免疫応答性細胞、薬物組成物、核酸、ベクター、宿主細胞、方法、及びキット
RU2025120810A (ru) Антитела против pdl1, полиспецифические антитела и способы их применения
IL321672A (en) Anti-pdl1/vegf antibodies and methods of use
RU2025120668A (ru) Антитела против pdl1/vegf и способы их применения
RU2023130041A (ru) Антитела, полиспецифические антитела к gpc3 и способы их применения
JP2024540604A5 (enExample)